Denali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03), Briefing.com reports. During the same period in the prior year, the company posted ($0.72) earnings per share.

Denali Therapeutics Stock Down 0.4 %

DNLI traded down $0.11 during trading on Thursday, reaching $29.44. The company had a trading volume of 466,777 shares, compared to its average volume of 1,070,667. The stock has a market cap of $4.21 billion, a P/E ratio of -10.37 and a beta of 1.40. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $32.13. The business has a 50 day simple moving average of $27.57 and a 200-day simple moving average of $23.36.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DNLI shares. Raymond James reiterated a "market perform" rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Citigroup raised their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Cantor Fitzgerald lowered shares of Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, October 7th. JPMorgan Chase & Co. reduced their target price on Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Finally, Jefferies Financial Group increased their price target on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $38.90.

Insider Buying and Selling at Denali Therapeutics

In other news, Director Steve E. Krognes sold 30,000 shares of the company's stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now directly owns 29,096 shares of the company's stock, valued at approximately $844,656.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Ryan J. Watts sold 40,000 shares of the company's stock in a transaction on Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares of the company's stock, valued at $6,529,495.83. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Steve E. Krognes sold 30,000 shares of the business's stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the transaction, the director now owns 29,096 shares of the company's stock, valued at approximately $844,656.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by corporate insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.